EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. SPGI
4. USO
5. ENOV

6. AON
7. AZN
8. AAPL
9. BLSM
10. A

Get Alerts EYPT Hot Sheet

Price: $4.45 -1.11%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

Cowen 43rd Annual Healthcare ConferenceForum: Fireside ChatDate: Monday, March 6, 2023Time: 9:10 a.m. ET

Guggenheim 4th Annual Healthy Altitudes SummitForum: Fireside ChatDate: Wednesday, March 15, 2023Time: 9:00 a.m. ET

A webcast and subsequent archived replay of each fireside chat, when available, may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:Anne Marie FieldsStern IRDirect: 332-213-1956[email protected]

Media ContactAmy PhillipsGreen Room CommunicationsDirect: 412-327-9499[email protected]